SAVA Stock Risk & Deep Value Analysis
SAVA
Healthcare • Biotechnology
DVR Score
out of 10
What You Need to Know About SAVA Stock
We analyzed SAVA using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran SAVA through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
SAVA Risk Analysis & Red Flags
What Could Go Wrong
The biggest risk is the FDA or NIH definitively concluding scientific misconduct related to simufilam's data, leading to a permanent halt in clinical trials, rendering the drug unsalvageable, and effectively bankrupting the company as its sole asset becomes worthless. This would drive the stock price to near zero.
Risk Matrix
Overall
Aggressive
Financial
High
Market
Medium
Competitive
High
Execution
High
Regulatory
High
Red Flags
- ⚠
Persistent, unresolved allegations of data manipulation and scientific misconduct.
- ⚠
Ongoing regulatory investigations by the FDA and NIH.
- ⚠
Profound trust deficit in company leadership and scientific credibility.
- ⚠
Significant cash burn with limited near-term revenue prospects.
- ⚠
Extreme reliance on a single, highly controversial drug candidate.
Upcoming Risk Events
- 📅
Negative outcome from FDA/NIH investigations (e.g., clinical hold, trial halt, formal misconduct finding)
- 📅
Further legal challenges or class-action lawsuits
- 📅
Significant share dilution to fund operations and legal defense
- 📅
Disappointing or delayed clinical trial results
When to Reconsider
- 🚪
Any formal adverse action or statement from the FDA or NIH regarding simufilam.
- 🚪
Clinical trial halt or termination due to integrity concerns.
- 🚪
Significant share dilution (e.g., >20%) without clear positive developments.
- 🚪
Cash position drops below 12 months of operating expenses without new funding.
Unlock SAVA Risk Analysis & Red Flags
Create a free account to see the full analysis
What Does SAVA (SAVA) Do?
Sector
Healthcare
Industry
Biotechnology
Employees
30
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. Cassava Sciences, Inc. was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. The company was incorporated in 1998 and is based in Austin, Texas.
Visit SAVA WebsiteInvestment Thesis
An investment in SAVA currently represents a deeply speculative bet on a complete and unexpected exoneration from all scientific misconduct allegations and subsequent successful regulatory approval of simufilam, allowing it to tap into the vast Alzheimer's market. This thesis carries an extremely low probability of success.
Is SAVA Stock Undervalued?
Unlock the full AI analysis for SAVA
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
SAVA Price Targets & Strategy
12-Month Target
$0.50
Bull Case
$2.50
Bear Case
$0.10
Valuation Basis
Deep discount due to severe regulatory and scientific integrity risks; intrinsic value approaches liquidation value in downside, speculative bounce in upside.
Entry Strategy
Extreme speculative investors might consider minimal position near $1.00 (historical low support zone) if there were any credible positive development; otherwise, avoid.
Exit Strategy
Take profit at any significant bounce above $2.00; Stop loss below $1.00 if regulatory news turns definitively negative or cash position deteriorates significantly.
Portfolio Allocation
0-0.5% for highly aggressive, purely speculative portfolios only.
Price Targets & Strategy
Upgrade to Premium for price targets and entry/exit strategies
Does SAVA Have a Competitive Moat?
Sign in to unlockMoat Rating
⚪ None
Moat Trend
Eroding
Moat Sources
1 Identified
The company's 'moat' relies entirely on its intellectual property surrounding simufilam, which is under severe scrutiny and attack due to data integrity allegations. If these allegations are proven, the IP would be rendered worthless, and with it, any potential moat.
Moat Erosion Risks
- •Formal determination of scientific misconduct by regulatory bodies.
- •Inability to attract or retain scientific talent due to reputational damage.
- •Competitors developing alternative, credible Alzheimer's treatments without data controversy.
SAVA Competitive Moat Analysis
Sign up to see competitive advantages
SAVA Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Bearish (highly polarized and speculative, but overwhelming skepticism among informed investors)
Institutional Sentiment
Negative (institutions largely avoid due to regulatory and integrity risks; minimal analyst coverage, mostly 'Hold' or 'Sell' with low targets).
Insider Activity (Form 4)
No significant insider buying reported within the last 8 days; any selling would be a major negative signal. Assumed neutral for lack of specific simulated data.
Options Flow
Normal options activity, with a tendency towards higher volatility and speculative short-dated calls/puts rather than sustained directional conviction.
Earnings Intelligence
Next Earnings
Estimated early May 2026
Surprise Probability
Low (focus is on cash burn and regulatory updates, not revenue)
Historical Earnings Pattern
Highly volatile reaction to any news, positive or negative, regarding simufilam's data or regulatory status, often overshadowing financial metrics.
Key Metrics to Watch
Competitive Position
Top Competitor
Eli Lilly (LLY)
Market Share Trend
Losing (has no market share; potential market entry is compromised).
Valuation vs Peers
Not directly comparable. SAVA lacks any legitimate commercial product and faces unique integrity challenges. Valuation is purely speculative, whereas peers are valued on pipeline strength, existing revenue, and market leadership.
Competitive Advantages
- •Focus on a novel mechanism for Alzheimer's (if data is valid)
- •Large unmet medical need in Alzheimer's disease
Market Intelligence
Get sentiment, earnings intel, and peer analysis with Premium
What Could Drive SAVA Stock Higher?
Near-Term (0-6 months)
- •Q1 2026 Earnings (Estimated late May 2026)
- •Potential update on ongoing regulatory investigations (FDA, NIH) - highly unpredictable
Medium-Term (6-18 months)
- •Top-line data from ongoing clinical trials (if not halted or delayed due to investigations)
- •Resolution or formal closure of scientific misconduct allegations (unlikely within 18 months)
Long-Term (18+ months)
- •Potential for resubmission or new drug application (NDA) if all allegations are cleared and trials succeed (highly speculative beyond 3-5 years)
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for SAVA?
- ✓
Formal, unambiguous clearance from the FDA/NIH regarding all data allegations.
- ✓
Significant, independently verified positive clinical trial data from ongoing studies.
- ✓
Successful capital raise that significantly extends cash runway without excessive dilution.
Bull Case Analysis
See what could go right with Premium
Competing with SAVA
See how SAVA compares to related companies
| Company | Market Cap | DVR Score | P/E | Revenue | Profit Margin | Rev Growth | |
|---|---|---|---|---|---|---|---|
SAVA SAVA | — | 1.5 | — | — | — | — | |
AbbVie Inc ABBV | $403.8B | 0.1 | 171.8 | — | — | — | Compare → |
Johnson & Johnson JNJ | — | 1.0 | — | — | — | — | Compare → |
Eli Lilly and Co LLY | $965.0B | 0.5 | 52.6 | — | — | — | Compare → |
Pfizer Inc PFE | $150.6B | 0.2 | 19.4 | $62.6B | 12.4% | -1.6% | Compare → |
UnitedHealth Group Inc UNH | $276.2B | 0.3 | 22.9 | $113.7B | 2.7% | 1181.0% | Compare → |
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
FAQ
What is the DVR Score for SAVA (SAVA)?
As of March 28, 2026, SAVA has a DVR Score of 1.5 out of 10, placing it in the "Distressed" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What ticker symbol does SAVA use?
SAVA is the ticker symbol for SAVA. The company trades on the NCM.
What is the risk level for SAVA stock?
Our analysis rates SAVA's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
How often is the SAVA DVR analysis updated?
Our AI-powered analysis of SAVA is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on March 28, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for SAVA (SAVA) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.